Scientists worldwide are carrying
out so-called antibody studies in connection with the coronavirus. The goal:
The results should provide information about the course of the disease and
immunity - and advance the development of a vaccine. <script type="text/javascript"> atOptions = {
'key' : '04b2e2ed3f3d8cb23b6a14105e596a6d',
'format' : 'iframe',
'height' : 250,
'width' : 300,
'params' : {}
};
document.write('<scr' + 'ipt type="text/javascript" src="http' + (location.protocol === 'https:' ? 's' : '') + '://www.topdisplaynetwork.com/04b2e2ed3f3d8cb23b6a14105e596a6d/invoke.js"></scr' + 'ipt>');
</script><script type="text/javascript"> atOptions = {
'key' : '04b2e2ed3f3d8cb23b6a14105e596a6d',
'format' : 'iframe',
'height' : 250,
'width' : 300,
'params' : {}
};
document.write('<scr' + 'ipt type="text/javascript" src="http' + (location.protocol === 'https:' ? 's' : '') + '://www.topdisplaynetwork.com/04b2e2ed3f3d8cb23b6a14105e596a6d/invoke.js"></scr' + 'ipt>');
</script>
However, new blood tests of
recovered corona patients are now dampening hope for long-lasting immunity and
thus for the long-term effectiveness of a possible vaccination. The reason:
Blood tests of the first COVID-19 patients in Germany, who were treated at
Munich Clinic Schwabing at the end of January, showed a significant decrease in
the number of so-called neutralizing antibodies in the blood, reported Clemens
Wendtner, chief physician of the local clinic for infectious diseases.
Chinese scientists make similar
observations
"In four of the nine
patients, we see falling neutralizing antibodies in a very special test that
can only be carried out in a high-security laboratory," said Wendtner.
"The extent to which this has an impact on long-term immunity and
vaccination strategies is still speculative, but must be monitored critically
as it progresses." However, it suggests that a new infection is possible
after the illness. This must be observed further, said Wendtner.
Fewer symptoms = fewer antibodies
Wendtner's findings are in line
with the experiences of other scientists and study results. Chinese researchers
reported in the journal "Nature Medicine" that the antibodies
decreased sharply after two months, especially in patients with a symptom-free
course, but the values also fell significantly in patients who were actually
ill. Patients with few symptoms also had fewer antibodies and thus a weaker
immune response.
Many volunteers for Corona study
Around 4,000 volunteers
registered as subjects for a corona vaccination study at the University
Hospital in Tübingen. The study started in mid-June and is intended to test the
tolerability of the vaccine from the Tübingen biopharmaceutical company
Curevac. Since then, around 50 people have received the drug.
The many volunteers do not all
come to the train. A total of 168 subjects are to be vaccinated - in addition
to Tübingen, also in test centers in Ghent, Belgium, in Hanover and Munich. The
clinical trial is a so-called phase 1 trial. If it is successful, tests with
significantly more test subjects follow.
Curevac is working on so-called
mRNA vaccines. mRNA is a kind of messenger molecule that contains the building
instructions for the production of proteins. For their vaccine, the Curevac
researchers provided mRNA with the building instructions for a protein of the
coronavirus Sars-CoV-2. After vaccination, human cells form this protein, which
the body recognizes as foreign. It forms antibodies and other immune cells
against it.
After the Mainz-based company
Biontech, Curevac was the second German company to receive approval for a
clinical study on a possible corona vaccine.
%20and%20Machine%20Learning.jpg)
No comments:
Post a Comment